0001213900-15-004749.txt : 20150625 0001213900-15-004749.hdr.sgml : 20150625 20150625170422 ACCESSION NUMBER: 0001213900-15-004749 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20150625 FILED AS OF DATE: 20150625 DATE AS OF CHANGE: 20150625 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BiondVax Pharmaceuticals Ltd. CENTRAL INDEX KEY: 0001611747 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1213 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37353 FILM NUMBER: 15952401 BUSINESS ADDRESS: STREET 1: 14 EINSTEIN ST. CITY: NES-ZIONA STATE: L3 ZIP: 74036 BUSINESS PHONE: 972-8-9302529 MAIL ADDRESS: STREET 1: 14 EINSTEIN ST. CITY: NES-ZIONA STATE: L3 ZIP: 74036 6-K 1 f6k062515_biondvaxpharma.htm REPORT OF FOREIGN PRIVATE ISSUER

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16

Under the Securities Exchange Act of 1934

 

For the Month of June 2015

 

001-37353

(Commission File Number)

 

BIONDVAX PHARMACEUTICALS LTD.

(Exact name of Registrant as specified in its charter)

 

14 Einstein St.

Ness Ziona

Israel 74036

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover

Form 20-F or Form 40-F.

 

Form 20-F þ    Form 40-F ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by

Regulation S-T Rule 101(b)(1): ____

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by

Regulation S-T Rule 101(b)(7): ____

 

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ☐    No þ

 

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-N/A

 

 

 

 
 

  

Below is an English translation (from Hebrew) from an immediate report by BiondVax Pharmaceuticals Ltd. (the "Company") as published on the Tel-Aviv Stock Exchange Ltd. and the Israeli Securities Authority on June 25, 2015, in accordance with the Israeli Security Regulations.

 

Re: Change in Senior Officers Holdings

 

Event 1

 

Name of holder

 

Uri Ben Or

 

The name in English

 

Uri Ben Or

 

ID type: Israeli Identification Number: 027867753

 

Type of holder: Executive Officer that is not a CEO or a director of the Company and is not an interested party by virtue of percentage of holdings.

 

Does the holder serve as the representative for reporting purposes of several shareholders who, jointly with him / her / it, hold corporation securities No

 

Nationality / country of incorporation or registration: An individual with Israeli citizenship

 

Security no. on TASE: 1105204

 

Name and Type of security: Ordinary Share

 

Nature of change: Increase due to a purchase of 5,000 American Depositary Shares as part of the exercise of the underwriter's over-allotment option in the IPO in the United States as reported on June 21, 2015, Reference No. 2015-01-052125.

 

Date of change: June 24, 2015. 

 

Quoted price: US$5.0

 

Are the ordinary shares treasury shares No

 

Balance in the previous summary report (the amount of securities): 0

 

Previous holding in Company shares: 0%

 

Change in the amount of securities: +200,000

 

Current balance (quantity): 200,000

 

Current holding in Company shares: 0.15%

 

Holding in Company shares after change: Equity: 0.15%; Voting power: 0.15%

 

Fully diluted holding in Company shares after change: Equity: 0.08%; Voting power: 0.08%

 

Date and time in which the Company was informed of event: June 24, 2015 18:00 (GMT +2)

 

2
 

 

Event 2

Name of holder

 

Tamar Ben Yedidia

 

The name in English

 

Tamar Ben Yedidia

 

ID type: Israeli identification Number: 058620253

 

Type of holder: Executive officer who is not a CEO or a director of the Company and is not an interested party by virtue of percentage of holdings.

 

Does the holder serve as the representative for reporting purposes of several shareholders who, jointly with him / her / it, hold corporation securities No

 

Nationality / country of incorporation or registration: An individual with Israeli citizenship

 

Security no. on TASE: 1105204

 

Name and Type of security: Ordinary Shares

 

Nature of change: Increase due to a purchase of 5,000 American Depositary Shares as part of the exercise of the underwriter's over-allotment option in the IPO in the United States as reported on June 21, 2015, Reference No. 2015-01-052125.

 

Date of change: June 24, 2015. 

 

Quoted price: US$5.0

 

Are the ordinary shares treasury shares No

 

Balance in the previous summary report (the amount of securities): 150,000

 

Previous holding in Company shares: 0.11%

 

Change in the amount of securities: +200,000

 

Current balance (quantity): 350,000

 

Current holding in Company shares: 0.26%

 

Holding in Company shares after change: Equity: 0.26%; Voting power: 0.26%

 

Fully diluted holding in Company shares after change: Equity: 0.14%; Voting power: 0.14%

 

Date and time in which the Company was informed of event: June 24, 2015 18:00 (GMT +2)

 

3
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  BiondVax Pharmaceuticals Ltd.
     
Date: June 25, 2015 By: /s/ Ron Babecoff
    Ron Babecoff
    Chief Executive Officer

 

 

4